Pharmaceutical Science, and Pharmacological and Biomolecular Science Departments, Italy (Coordinating University)
Institute of Medical Science, School of Medicine, Medical Science and Nutrition, UK
Laboratory of Physiopharmacology, Belgium
Department of Biochemistry and Molecular Biology, Spain
Department of Surgery and Einthoven Laboratory for Experimental Vascular Medicine, The Netherlands
Marie Skłodowska-Curie ITN-European Joint Doctorate
Public Dissemination for Secondary School Students
“Tu lo conosci il Farmaco? ”
University of Milan, Italy
March 6th, 2018
Marie Skłodowska-Curie ITN-European Joint Doctorate
MOGLYNET-PhD programme in drug discovery and development
The Horizon 2020 MSCA joint doctoral project MoGglyNet (“Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study”) is running by a Consortium of Universities in cooperation with Pharma Industries and Associations. The programme was established with the aim of providing 12 Early Stage Researchers with innovative PhD trainings in Drug Discovery and Development.
The MOGLYNET PhD programme aims to define a new joint PhD educational model in Drug Discovery and Development and to promote institutional cooperation and mobility.
An active contribution of Industry in training activities is an important feature of the programme. The research methodologies and approaches proposed by the MOGLYNET consortium are strongly multidisciplinary and will involve a number of different state-of-the-art technologies and methodologies. These includes computational chemistry, chemical synthesis, bioanalytics, biophysics, in vitro biological evaluations, in vivo studies, imaging, metabolomics, proteomics, and oxidative stress studies.
WE SEE THE FUTURE
MOGLYNET IN NUMBERS
WHAT WE THINK ABOUT MOGLYNET
Nukala Sarath Babu
I strongly believe that the anticipated multidisciplinary approaches meet the eminent level of state-of-the-art technology in the field of atherosclerosis. The excellence of the MOGLYNET innovative training program and the proposed strategies provides the ideal evidence to develop the new effective therapeutic agents.
Working together towards a common goal. That's teamwork.
Moglynet project is a great opportunity for an international experience as well as for success in the future career.
Moglynet is a programme bringing elites together from multidisciplinary fields and contributing to the welfare of the public. I'm proud to be part of it.
De Dominicis Carlo
This project involves some of the best European universities and important companies and associations operating in the Pharma sector. This is an extraordinary opportunity and can give me a very high level training in drug discovery and development. Besides, I do believe that the opportunity to work in an international environment can accelerate my growth and always provide me with new challenges and stimuli.
Moglynet, a europass to Europe and a worldpass to knowledge.
I am really excited to be part of the MoGlyNet consortium. We are a group of 12 students from different countries and universities. Our mission is to discover new pharmacological approaches to treat atherosclerosis, a disease that lead to loss of many lives every year. Our strategy is dedication, team work and sharing of information. Our driving force is the curiosity for new knowledge and we look forward to contribute to the progress of scientific research for improving people's health.
Baganha Carreiras Fabiana
As a early stage researcher number 5 of the Moglynet PhD Program, I can tell how exciting and challenging will be the next years. We are a team of 12 PhD students, having the best training in different scientific fields, with a common goal. I'm sure that we will do good science.
The Moglynet consortium is a great opportunity to work on an innovative project together with others early stage researchers, sharing knowledge and learning, thanks to the home university supervision and both the secondments and the workshops/summer schools.
A unique program bringing people together from over the world to achieve one goal: improving pharmacological interventions for both atherosclerosis and Chronic Thromboembolic Pulmonary Hypertension. The project highlights a strong intersectional research cooperation which will provide specific training skills for future researchers.
The great thing about this program is that you meet students, researchers and professionals from different backgrounds and countries. Moglynet offers me a great opportunity to pursue an international career within academia and industry.
I find extremely fascinating the possibility of developing models able to assess the bioactivity and effectiveness of new drugs and it is my intention to bring my personal contribution to this research area.
Dr.ssa Anni Svala
The non-academic contribution provides the way forward to help academia in meeting the educational needs of pharmaceutical industry.
Prof.ssa Marina Carini
The exposure of recruited researchers to different environments is specifically designed to integrate and complement the sectorial knowledge of the fellow allowing the creation of a common knowledge and language for ESRs.
Dr. Stefano Bellosta
Synergy between all the participants is fundamental to reach the goals planned by MOGLYNET programme.
Prof. Matteo Zanda
MOGLYNET EJD stems from six Doctoral Courses/Schools at the five beneficiary institutions providing research and training in the field of drug discovery and health. A double degree in Drug Discovery and Development will be delivered by two Accademic beneficiaries.
Dr.ssa Mirela Delibegovic
The research methodologies and approaches proposed by the MOGLYNET consortium are strongly multidisciplinary (from molecular modelling to in vivo studies) and will involve a number of different state-of-the-art technologies and methodologies.
Prof. Guido De Meyer
We are a consortium of excellence in the atherosclerosis field. The research strategy proposed by MOGLYNET to takle atherosclerosis, which is a major unmet medical need, is higly original and innovative.
Prof. Paul Quax
Atherosclerotic cardiovascular disease is a disease of aging and is the major cause of death in the western world and for this reason there is a strong high need for additional pharmacological interventions.
Prof. Francesca Clerici
The European Commission has identified active and healthy aging as a major societal challenge common to all European countries, and an area which presents considerable potential for Europe to lead the world in providing innovative responses to this challenge.
Prof. Maria Luisa Gelmi
The transfer of “what” a researcher know in “how” to realize this in a complex system related to the drug is not trivial and requires a wide overall view of the problem. The mission of MOGLYNET is to define a joint doctorate educational training model where Academia and Industry Join their forces to reach this target.
We are the MOGLYNET-PhD programme in drug discovery and development.
The Horizon 2020 MSCA joint doctoral project MOGLYNET (“Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study”) is run by a Consortium of Universities in cooperation with Industries and Associations operating in the Pharma sector with the aim to offer an innovative PhD level training in Drug Discovery and Development to 12 Early Stage Researchers